Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Paychex Non-GAAP EPS of $1.19 in-line, revenue of $1.43B in-line; initiates FY outlook (SeekingAlpha) +++ PAYCHEX Aktie -4,30%

IDEAYA Aktie

 >IDEAYA Aktienkurs 
18.9 EUR    (Tradegate)
Ask: 19 EUR / 200 Stück
Bid: 18.8 EUR / 200 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
IDEAYA Aktie über LYNX handeln
>IDEAYA Performance
1 Woche: -1,8%
1 Monat: +13,3%
3 Monate: +9,0%
6 Monate: -22,8%
1 Jahr: -45,5%
laufendes Jahr: -22,2%
>IDEAYA Aktie
Name:  IDEAYA BIOSCIENCE DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US45166A1025 / A2PJPB
Symbol/ Ticker:  30J (Frankfurt) / IDYA (NASDAQ)
Kürzel:  FRA:30J, ETR:30J, 30J:GR, NASDAQ:IDYA
Index:  -
Webseite:  https://www.ideayabio.com..
Marktkapitalisierung:  1680 Mio. EUR
Umsatz:  6.08 Mio. EUR
EBITDA:  -310.82 Mio. EUR
Gewinn je Aktie:  -2.77 EUR
Schulden:  22.55 Mio. EUR
Liquide Mittel:  601.28 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / 9.49
KUV/ KBV/ PEG:  260.84 / 1.84 / -
Gewinnm./ Eigenkapitalr.:  - / -31.34%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  IDEAYA
Letzte Datenerhebung:  25.06.25
>IDEAYA Eigentümer
Aktien: 87.58 Mio. St.
f.h. Aktien: 86.79 Mio. St.
Insider Eigner: 0.9%
Instit. Eigner: 112.28%
>IDEAYA Peer Group

 
02.06.25 - 12:03
 IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., June 2, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. 2025......
30.05.25 - 12:01
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., May 30, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 29, 2025, the Compensation Committee of IDEAYA's Board......
06.05.25 - 15:45
 IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.25 - 12:30
 IDEAYA Biosciences GAAP EPS of -$0.82 misses by $0.15 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.25 - 12:06
 IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
 
~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting......
06.05.25 - 12:01
 IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors (PR Newswire)
 
Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durability Targeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner......
28.04.25 - 12:03
 IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., April 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Barclays......
25.04.25 - 12:00
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., April 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 24, 2025, the Compensation Committee of IDEAYA's......
14.04.25 - 12:03
 IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire)
 
Targeting to initiate Phase 3 randomized registrational trial for darovasertib in the neoadjuvant setting in primary UM in H1 2025 Clinical endpoints supportive of full approval based on FDA Type D Meeting: Eye preservation rate as the primary endpoint for enucleation patients. Proportion......
10.04.25 - 12:01
 IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer (PR Newswire)
 
Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy®, Gilead's Trop-2 directed ADC, in MTAP-deletion urothelial cancer based on preliminary safety and clinical efficacy data MTAP-deletion prevalence in urothelial cancer is estimated to be......
01.04.25 - 12:01
 IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., April 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. 2025 RBCCM......
31.03.25 - 12:01
 IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma (PR Newswire)
 
Designation enables expedited development and priority regulatory review BTD application was supported by updated clinical data from Ph2 neoadjuvant UM trial that we are targeting to present at medical conferences in mid-2025 and H2 2025 Targeting to initiate a Ph3 registrational study in......
28.03.25 - 11:03
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., March 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 27, 2025, the Compensation Committee of IDEAYA's......
26.03.25 - 11:03
 IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor (PR Newswire)
 
4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a potential best-in-class preclinical profile in the MSI-H setting, with a unique binding mode from......
03.03.25 - 12:01
 IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to......
28.02.25 - 12:03
 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
 
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on February 27, 2025, the Compensation Committee of IDEAYA's......
13.02.25 - 14:30
 IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss (Zacks)
 
IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -122.39% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...
13.02.25 - 12:12
 IDEAYA Biosciences GAAP EPS of -$1.49 misses by $0.86, revenue of $0.7M misses by $3.61M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.25 - 19:45
 All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy (Zacks)
 
IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
10.02.25 - 12:24
 IDEAYA Biosciences names Joshua Bleharski as CFO (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!